Medtronic Delivers Strongest Quarterly Results in Eight Years as Market Focus Shifts to Growth Sustainability
Alina Collins
Medtronic's FY4Q26 revenue hit $9.81 billion with 6.6% organic growth — its best single quarter in nearly eight years — sending shares higher after hours; but operating margins slipped and EPS guidance fell short, leaving one real question: how long can this pace hold?
What exactly made this quarter so strong?
Revenue of $9.81 billion beat the FactSet consensus of $9.62 billion; EPS of $1.55 edged out the $1.54 expectation — a near-clean sweep.
Gross margin expanded from 65.1% to 65.4%. This means → the product mix is shifting toward higher-margin offerings.
But operating margin fell from 27.8% to 25.5%, missing the 27.0% consensus — SG&A expense ratio climbed to 30.4%. In plain terms = revenue grew faster, but spending grew faster still. That "top-line hit, bottom-line miss" tension is the headline contradiction.
Why is cardiac ablation the biggest surprise?
Cardiac Ablation Solutions (CAS — treatments that use energy to destroy abnormal electrical pathways in the heart) surged 78% globally, with U.S. sales up 124%, contributing roughly 390 basis points of overall growth.
Sphere-9 pulsed-field ablation catheter penetration kept climbing; Affera system U.S. installs jumped 40% quarter-over-quarter. This means → it is not just unit sales — the installed base is expanding fast, locking in the ecosystem.
Citi analyst Joanne Wuensch noted CAS is on track to cross $2 billion in trailing-twelve-month revenue by FY1Q27. Management expects the market to grow at mid-to-high teens, with Medtronic's own pace at more than 2× the market rate.
Beyond cardiac ablation, what else is accelerating?
Renal denervation (RDN — a minimally invasive procedure that uses radiofrequency energy on kidney nerves to treat hypertension): after the February 2026 national coverage determination, weekly Symplicity procedure volumes doubled, annualized revenue reached $100 million, and private-payer prior-authorization approvals rose markedly.
Hugo robotic surgery system: the first U.S. case is done; 510(k) submissions for general surgery and gynecology went to the FDA in late April 2026. Approval would significantly expand the addressable market. Global Hugo procedure volume is growing at 2–3× the market rate, now covering 1,400 operating rooms.
CAS ecosystem expansion continues: next-gen Prism 2 mapping software is rolling out globally; the single-shot Sphere 360 catheter has EU CE marking; the FDA has greenlit a pivotal trial for ventricular tachycardia, expected to start in FY1H27. This reflects a shift from a single breakout product to a broader platform.
What did the FY27 guidance say — and what did it hide?
Organic revenue growth guided at 6.75%–7.25%, implying roughly $38.7–39.0 billion — above the 6.41% consensus. On the surface, bullish.
But EPS guidance of $5.90–6.00 came in below the $6.09 consensus. In plain terms = management is saying "revenue will be strong, but profit won't keep up as fast."
Several pieces of "technical noise" sit inside the guidance: a 53rd selling week adds 500–600 bps to 1Q27 growth; tariff headwinds of roughly $250 million with no relief assumed; MiniMed consolidation dilutes EPS by about $0.08–0.10; Middle East disruptions drag transport costs by roughly 1%.
The valuation looks cheap — so what is the market worried about?
At $77.95, the stock trades at roughly 13.1× Citi's FY27E EPS — a clear discount to med-tech peers. Citi values it at 17–18× CY27E EPS, yielding a $110 target with over 41% implied upside.
This means → if you believe growth is durable, the price is genuinely cheap. But the discount exists for a reason.
The core question: can CAS sustain this pace? Competitors are catching up, and as pulsed-field ablation technology diffuses, deceleration is near-certain. TAVR — weighed down by six-year low-risk trial data — left the structural heart segment flat year-over-year, and U.S. softness there still needs time to digest. This reflects a market that is not pricing "was this quarter good?" but rather "can the next several quarters be this good?"
Content is for reference only, not financial advice.